NGF encodes nerve growth factor (241 aa). Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Highest expression in Ovary (33.5 TPM) and Artery Aorta (30.0 TPM).

Hereditary sensory and autonomic neuropathy type 5 is associated with mutations in the NGF gene on chromosome 1.

The NGF protein participates in NGF ligand:p75NTR:NRIF:TRAF6 pathway.

NGF is classified as a druggable target (Druggable Genome, Growth Factor, and Kinase categories) with score 17.4.

Genetic testing for NGF is available. Testing is considered confirmatory for diagnosis.

Phenotype severity distribution: 4 always present features, 11 common features.

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

No clinical trials have been registered for hereditary sensory and autonomic neuropathy type 5.

4 publications have been identified in PubMed for hereditary sensory and autonomic neuropathy type 5. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (25%).

Recent Publications

• Ren Y (2026). [PMID: 42033181](https://pubmed.ncbi.nlm.nih.gov/42033181/). *Eur J Neurol*. [Basic Science / Preclinical]

• Li J (2025). [PMID: 40205342](https://pubmed.ncbi.nlm.nih.gov/40205342/). *BMC anesthesiology*. [Case Report / Case Series]

• Rodríguez-Blanque R (2024). [PMID: 38929791](https://pubmed.ncbi.nlm.nih.gov/38929791/). *Journal of personalized medicine*. [Review / Meta-Analysis]

• Sreenivasan V (2024). [PMID: 38659257](https://pubmed.ncbi.nlm.nih.gov/38659257/). *Paediatrics and international child health*. [Case Report / Case Series]